Although sustained production of committed human hematopoietic progenitor cells in long-term bone marrow cultures (LTBMC) is well documented, evidence for the generation and expansion of human primitive hematopoietic progenitor cells (PHPC) in such cultures is lacking. For that purpose, we attempted to determine if the human high proliferative potential colony-forming cell (HPP-CFC), a primitive hematopoietic marrow progenitor cell, is capable of generation and expansion in vitro. To that effect, stromal cell-free LTBMC were initiated with CD34+ HLA-DR-CD15-rhodamine 123dU1' bone marrow cells and were maintained with repeated addition of c-kif ligand and a synthetic interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein. By day 21 of LTBMC, a greater than twofold increase in the number of assayable HPP-CFC was detected. Furthermore, the production of HPP-CFC in LTBMC continued for up to 4 weeks, resulting in a 5.5-fold increase in HPP-CFC numbers. Weekly phenotypic analyses AJOR STRIDES have been recently made in the
M identification and isolation'-3 as well as the in vitro3-7 and in vivo8 characterization of human primitive hematopoietic progenitor cells (PHPC). Long-term in vivo bone marrow (BM) repopulating ability has been universally accepted as the ultimate test by which the potential of PHPC can be adequately assessed.' Such an approach using an allogeneic system is difficult to implement for the examination of human PHPC. Instead, several groups of investigators,1°-12 ourselves i n c l~d e d ,~* l~ have recently developed hematopoietic chimeras in immunodeficient animals or have developed in vitro systems designed to study one or more functions of human PHPC.",14-18 Many of these assays can be used as tools for the examination of functional properties and proliferative potential of PHPC in vitro.
Among the in vitro assays, one in particular, the long-term BM culture (LTBMC) offers a unique approach to investigate human hematopoiesis. Since Dexter et all' described the conditions conducive for the establishment of in vitro longterm hematopoiesis, LTBMC initiated over a monolayer of preestablished adherent stromal cell layer have been extensively used for the in vitro examination of murine and human hematopoiesis. 14~1520321 Recently, we described a stromal cellfree suspension culture system in which populations of human BM progenitor cells are maintained by repeated supplementation with exogenous ~y t o k i n e s .~.~~ With minor modifications, this type of LTBMC has been used by other investigators to expand BM and peripheral blood progenitor cells in ~itro.','~,~~ Both types of LTBMC are capable of generating large numbers of progenitor cells and are capable of sustaining multilineage hematopoiesis for up to 10 to 12 ~e e k s .~~,~~,~~,~~,~~ To date, it remains unknown whether the PHPC used to initiate LTBMC are able to undergo self-renewal, a cardinal function that prevents stem cell extinction. It is possible that self-renewal has not been previously documented using these systems because the microenvironment of the LTBMC favors PHPC proliferation and differentiation rather than self-renewal. Alternatively, the sustained hematopoiesis frequently of cells harvested from LTBMC showed that the number of CD34+ HLA-DR-cells increased from 1 O4 on day 0 to 56 X 1 O4 by day 21. To examine further the nature of the in vitro HPP-CFC expansion, individual HPP-CFC colonies were serially cloned. Secondary cloning of individual, day 28 primary HPP-CFC indicated that 46% of these colonies formed an average of nine secondary colony-forming unitgranulocyte-macrophage (CFU-GM)-derived colonies, whereas 43% of primary HPP-CFC gave rise to between one and six secondary HPP-CFC colonies and 6 to 26 CFU-GM. These data show that CD34+ HLA-DR-CD15-rhodamine 1 23du1' cells represent a fraction of human bone marrow highly enriched for HPP-CFC and that based on their regeneration and proliferative capacities, a hierarchy of HPP-CFC exists. Furthermore, these studies indicate that in the presence of appropriate cytokine stimulation, it is possible to expand the number of PHPC in vitro.
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observed for 12 or more weeks during LTBMC clearly indicates that PHPC self-renewal does likely occur, albeit to a limited degree. In addition, our inability to document PHPC self-renewal in vitro might also be caused in part by the lack of established criteria by which to evaluate such an event.
Recently, assays for the high proliferative potential colonyforming cell (HPP-CFC) have been described both in and humanz8~'' BM. These macroscopic colonies are derived from primitive hematopoietic progenitor cells that resemble hematopoietic stem cells. Optimal HPP-CFC cloning efficiency is best achieved by addition of combinations of growth factors rather than by addition of individual cytokines.17,27,28*30,31 HPP-CFC along with the colony-forming unit-blast (CFU-Bl) and the LTBM culture-initiating cell (LTBMC-IC), represent the most PHPC that can be presently assayed in Despite reports showing a direct correlation between HPP-CFC and in vivo spleen colonyforming unit (CFU-S),33,34 it has been shown that even though HPP-CFC can be assayed from Scaf Lin-and Sca-Linmurine BM cells, albeit to a different degree, only Scat Lincells possess BM repopulating capacity.35 662 SROUR ET AL 1 U human purified erythropoietin, 10 ng/mL c-kit ligand, 10 ng/mL FP, and 1.1 % methylcellulose in IMDM.
We have shown that human CD34' HLA-DR-CD15-BM cells, which are highly enriched for PHPC, can be further fractionated based on their relative reactivity with the mitochondrial-specific dye rhodamine 123 ( R 1 2 3 ) . "~~~ A fraction of CD34+ HLA-DR-CD15-cells identified by their limited uptake of R123 (R+ cells) has been documented to contain the majority of human PHPC, including HPP-CFC and the LTBMC-IC. '7,36 It was reasoned that R+ cells maintained in a stromal cell-free LTBMC system supplemented with appropriate cytokines could be used to quantitate generation and expansion of HPP-CFC in vitro. The continued presence and detection of cells expressing the original phenotype of the cultured cells was also used as an alternate means of monitoring this process. The studies reported here indicate that generation and expansion of both PHPC and CD34+ HLA-DR-cells in response to cytokine stimulation does occur in vitro and that, although such events may not directly show self-renewal in LTBMC, they could help identify conditions conducive to and parameters with which in vitro self-renewal might be assessed.
MATERIALS AND METHODS
BM cell3 und cell separution techniques. BM aspirates were collected in heparinized Iscove's modified Dulbecco's medium (IMDM) from normal healthy volunteers after obtaining informed consent. Low-density mononuclear cells were separated over Ficoll-Paque (specific gravity 1.077 g/mL Pharmacia Fine Chemicals, Piscataway, NJ). Counterflow centrifugal elutriation of low-density BM cells was then performed as previously de~cribed.~ Briefly, cells were injected in phosphate-buffered saline (PBS), pH 7.4, containing 5% fetal bovine serum (FBS), 0.01% EDTA wt/vol, and 1.0 g/L D-glucose into an elutriator system with a standard separation chamber (Beckman, Palo Alto, CA). Rotor speed and temperature were maintained at 1,950 rpm and 10°C. Fractions eluting at a flow rate of 12 and 14 mL/ min (FR 12-14) were collected, pooled, and used for cell staining and sorting.
Monoclonal antibodies CD34 (purified HPCA-I, IgG, isotype, and fluorescein isothiocyanate (F1TC)-conjugated HPCA-2), CD15 (Leu-M I, IgM isotype), and phycoerythrin (PE)-conjugated HLA-DR (IgG2, isotype) were obtained from Becton Dickinson lmmunocytometry Systems, San Jose, CA. FITC-conjugated QBEND 10 (CD34) was obtained from AMAC, Westbrook, ME. R123 and allophycocyanin (APC)-streptavidin were obtained from Molecular Probes, Eugene, OR. Texas red (TR)-conjugated goat-anti-mouse IgG, and biotinylated goat-anti-mouse IgM were obtained from Southern Biotechnology, Birmingham, AL. Cell staining for four-color flow cytometric cell sorting using R123, PE, TR, and APC has been previously described. 36 Briefly, cells washed with PBS supplemented with 2% (wt/vol) bovine serum albumin (BSA) were first incubated for 20 minutes with appropriate amounts of CD34 and CDl5 simultaneously. Following that, TR-conjugated goat-anti-mouse IgG, and biotinylated goatanti-mouse 1gM were added to develop the CD34 and CD15, respectively. Mouse myeloma proteins were then added to block free active sites on the second-step reagents. Finally PE-conjugated HLA-DR, R123 (used at 1 pg/mL) and APC-streptavidine were added
Immunofluorescence staining and cell sorting. t Sorted R' and R" cells were maintained in 1 mL of IMDM containing 10% FCS and were supplemented by the addition of 10 ng/mL FP and 25 ng/mL c-kif ligand every 48 hours. Harvested cells at various concentrations were assayed for CFU-GM and HPP-CFC in 35-mm tissue culture dishes as described in Table 1 . CFU-GM-derived colonies and HPP-CFC were enumerated on days 14 and 28, respectively, and based on the number of total viable cells per culture from Table 2 , the total number of colonies per culture was calculated. The assay of CFU-MK-derived colonies was performed in 1 mL serum-substituted fibrin clot to which IO5 cells and 100 U IL-3 were added. Colonies were enumerated after 14 to 18 days of incubation using rabbit anti-human platelet glycoprotein antisera. The number of CFU-MK colonies was corrected to reflect the total number/culture. together. Cells were then washed with PBS-BSA. Each incubation step was for 20 minutes and the cells were kept at 4°C in the dark throughout staining and cell sorting. Conjugated and purified isotypematched nonspecific myeloma proteins were used to determine background fluorescence and establish positivity as previously described.36 When R123 was not used in cell staining, FITC-conjugated CD15 (BDIS, San Jose, CA) was substituted for purified CD15 in conjunction with PE-conjugated HLA-DR and CD34, which was developed with a TR-conjugated second-step reagent.
Cell sorting was performed on a Coulter Epics 753 dual laser flow cytometer (Coulter Corp, Hialeah, FL) capable of simulbneously detecting five parameters and equipped with a CICERO high-speed cell sorting computer (Cytomation, Fort Collins, CO). Cytometer settings capable of adequately measuring R123 and PE fluorescences simultaneously as well as specifications of optical filters used to separate the four different wavelengths generated from the four fluorochromes have been previously described.36 A gating bit map generated on a dual fluorescence (TR/PE) histogram was first constructed to select for CD34+ HLA-DR-cells. This allowed for the generation of a single fluorescence R123 histogram gated on forward angle light scatter, the preestablished CD34' HLA-DR-gating bit map and CDI 5 negative events. Two sets of sorting windows were then established in order to divide the CD34+ HLA-DR-CD15-cells into R123d"11 (R') and R123b"@" (R++) subpopulations. Sorted R+ and R++ cells each represented approximately one third of the CD34+ HLA-DR-CDI 5-events. These selection criteria were based on a previously described rationale." Cells were sorted at a rate of 3,000 to 4,000 cells per second. Postsort cell viability, as determined by trypan blue exclusion, was always greater than 96%.
Staining of cultured cells for cell cycle analysis was performed according to published methodol~gies.~~ Briefly, cells collected from LTBMC were stained with equal volumes of staining buffer (0. I mg/mL propidium iodide + 0.6% Nonidet P-40 in PBS) and 2 mg/mL RNase. The samples were then agitated and kept on ice in the dark for 30 minutes then analyzed on a FACScan flow cytometer calibrated with chicken erythrocytes. For each sample, 5 to IO X IO3 cells were analyzed using the SFIT software (BDIS) to determine the percentage of cells in the Go + GI (G,,/G,), the S, and the Gz + M phases of the cell cycle. Cultured cells were also stained at different time intervals with FITC-conjugated CD34 (HPCA-2, DNA analysis.
BDIS, or QBENDIO AMAC) and PE-conjugated HLA-DR and analyzed for the expression of these markers on a FACScan flow cytometer.
Stromal cell-free LTBMC were initiated and maintained as previously described!."
Sorted cells were seeded on day 0 at IO4 cells/mL in flat-bottomed 24-well plates in IMDM supplemented with 10% fetal calf serum (FCS), and incubated in 100% humidified 5% COz in air. At day 0, and every 48 hours thereafter, cultures were fed with 1% BSA/PBS (control group), 10 to 25 ng ckit ligand, 10 ng fusion protein (FP) (synthetic interleukin-3/granulocyte-macrophage colony-stimulating factor [IL-3/GM-CSF] molecule, PlXY321) or a combination of both. (The c-kit ligand and FP were a gift from Immunex, Seattle, WA.) At weekly intervals, cultures were demi-depopulated by the removal of half the culture volume, which was then replaced by fresh medium and cytokines. Cells in the collected media were counted, stained for phenotypic analysis, and assayed for various progenitor cells. Cultures intended for phenotypic and cell cycle analyses only were initiated with 5 X IO4 sorted cells and were terminated after 1 week.
Freshly sorted cells from LTBMC were suspended at different cell concentrations in 35-mm tissue culture dishes (Costar Data Packaging, Cambridge, MA) containing I mL of 30% FCS, 5 X mol/L 2-mercaptoethanol, 1 U human purified erythropoietin (50 U/mg protein; Toyobo Company Ltd, Osaka, Japan), 10 ng/mL c-kit ligand, 10 ng/ml FP, and 1.1% methylcellulose in IMDM. Cultures were incubated at 37°C in 100% humidified 5% COz in air. Erythropoietic bursts (BFU-E), granulocytemacrophage (CFU-GM), and mixed lineage (CFU-GEMM) colonies were enumerated 14 days later, whereas HPP-CFC-derived colonies were enumerated on day 28 according to previously established criteria.'~~ Cells harvested from LTBMC were assayed for CFU-megakaryocyte (CFU-MK) colonies in a serum-depleted method previously detailed by Bruno et Cells were suspended in a I-mL serum-substituted fibrin clot with 100 U IL-3 in 35-mm culture dishes and incubated at 37°C in a 100% humidified atmosphere containing 5% COz in air. Two weeks to 18 days later the cultures were fixed in situ and stained using rabbit anti-human platelet glycoprotein antisera, and FITCconjugated goat F(ab)z-specific anti-rabbit IgG (Tago, Inc, Burlingame, CA). MK colonies were enumerated on a fluorescence micro-
LTBMC.
Hematopoietic progenitor cell assays.
For Tables 2 and 3. scope and a positive colony was defined as a cluster of three or more fluorescent cells.
Secondary replating of primary HPP-CFC-derived colonies.
HPP-CFC colonies growing in semisolid medium were plucked on day 28 from the methylcellulose under direct microscopic visualization using sterile 100 r L glass micropipettes (Drummond Scientific Company, Broomall, PA) and suspended in 200 r L IMDM. The cell suspension was then made up to 1 mL, containing at a final concentration 1.1% methylcellulose, 30% FBS, 5 X mol/L 2-mercaptoethanol, I U human purified erythropoietin, 10 ng/mL c-kit ligand, and IO ng/mL FP, which was then transferred entirely into a single well of a 24-well tissue culture plate (Coming Glass Works, Corning, NY). Plates were incubated at 37°C in 100% humidified air with 5% COz. Secondary CFU-GM-and HPP-CFC-derived colonies were enumerated 14 and 28 days later, respectively, as described above.
RESULTS

R+ cells are enriched for HPP-CFC. Before using R+ cells
for experiments aimed at expanding PHPC in vitro, it was important to establish the HPP-CFC content of BM populations isolated on the basis of their staining with R123. Hematopoietic progenitor cell assays of sorted R+ and R++ cells showed that between 9% and 43% of CFU-GM, BFU-E, and CFU-GEMM cloned from CD34+ HLA-DR-CDl5-marrow cells were present in the R++ fraction. On the other hand, the majority of assayable HPP-CFC were found in R+ cells ( Table 1) .
Cell and HPP-CFC expansion in LTBMC. Cellular content as well as numbers of progenitor cells in both R+-and R++-initiated LTBMC increased during the culture period, albeit to a different magnitude and at different rates. In response to repeated additions of c-kit ligand and FP, cellular expansion in R+ cultures reached its peak at week 6 with more than a 1.500-fold increase in cell number (Table 2) . Under the same conditions, a mere sevenfold increase in cell number at week 3 was observed in R++ LTBMC. Only LTBMC initiated with R+ cells continued to produce cells for 10 weeks, indicating that LTBMC-IC were primarily present in the R+ fraction of CD34+ HLA-DR-CD 15-BM cells.
We have previously shown that without continued cytokine supplementation, cell expansion and production of progenitor cells in stromal cell-free LTBMC cannot be maintained.4." Based on this and because of the difficulty of obtaining large numbers of R+ cells, LTBMC to which no exogenous cytokines were added were not initiated.
To monitor the expansion of HPP-CFC during the period of LTBMC, one half of the cells in R+-and R++-initiated LTBMC was removed at weekly intervals and assayed for HPP-CFC as well as for CFU-GM-and CFU-MK-derived colonies. LTBMC initiated with R++ cells did not contain any assayable CFU-GM, HPP-CFC, or CFU-MK progenitor cells after 3 weeks of culture (Table 3) . However, CFU-GM- Sorted R+ cells were maintained in 1 mL IMDM containing 10% FCS and were supplemented by the addition of 10 ng/mL FP and 2 5 ng/mL c-kif ligand every 48 hours.
t Viable cell number = cells/mL culture/(%)", where n = number of previous demi-depopulations. and CFU-MK-derived colonies continued to be present after 8 weeks in cultures initiated with R+ cells (Table 3 ). In R+-initiated cultures, HPP-CFC were assayable 4 weeks after the initiation of the cultures but not by week 6. Over a period of 3 weeks, more than a twofold increase in the number of HPP-CFC originally present in the culture at day 0 was detected. Furthermore, there was an overall 5.5-fold increase in HPP-CFC numbers during the entire period of LTBMC. Similar data were observed in two other experiments. However, the degree of HPP-CFC expansion varied among cultures such that one LTBMC initiated with R+ cells resulted in a more than eightfold increase in the number of assayable HPP-CFC at week 3 (data not shown).
To examine, in an alternative fashion, the capacity of R+ cells to support in vitro expansion of PHPC, the number of cells displaying the original CD34' HLA-DR-phenotype was monitored during the period of LTBMC. The loss of CD34 expression or the acquisition of HLA-DR have been shown to occur in differentiating hematopoietic cells in vitro.38 Results generated from three consecutive weekly analyses of the LTBMC described in Tables 2 and 3 are shown in Fig 1. Compared with the isotype control, 37% of the cells after 14 days in culture in the presence of c-kit ligand and FP displayed the original CD34' HLA-DR-phenotype (Fig 1 B) . The percentage of CD34' HLA-DR-cells in these cultures at weeks 3 and 4 decreased to 13% and 2%, respectively (Fig IC and  D) . However, this cell population was undetectable by week 5.
We then determined the absolute number of CD34+ HLA-DR-cells present in LTBMC at different time points (Table  4) . Such calculations showed 44-and 55-fold increases in the number of CD34+ HLA-DR-cells detected at 2 and 3 weeks of LTBMC, respectively, when compared with the original Expansion of CD34' HLA-DR-cells in vitro.
cell number present at day 0. A rapid and complete decline in the number of CD34+ HLA-DR-cells occurred by week 6. It should be pointed out that the presence of assayable HPP-CFC in LTBMC correlated with the presence of CD34+ HLA-DR-cells in these cultures.
Effect of cytokines on expansion of CD34+ HLA-DRcells. We next examined which cytokines were responsible for the expansion of PHPC in vitro. Because sufficient numbers of R+ and R' + cells needed for such studies are difficult to isolate from BM aspirate samples,36 and R123 fluorescence persists in isolated cells for prolonged periods preventing further accurate flow cytometric analysis, CD34' HLA-DR-CD15-cells were used in these studies. This cell subpopulation was cultured for 7 days in the presence of c-kit ligand and FP, alone or in combination, and cells were then analyzed for CD34 and HLA-DR expression and cell cycle status. The results of such analyses are shown in Fig 2. Measurement of forward angle light scatter, which is a direct reflection of cell size, indicated that cells exposed to c-kit ligand were considerably smaller than cells cultured in the presence of FP or FP plus c-kit ligand. In addition, 68% of cells exposed to ckit ligand expressed CD34 and 75% of these cells remained in Go/GI. Relative to the cell number at day 0, only a 1.1-fold increase in cell number was detected in these LTBMC. By contrast, 88.5% of cells receiving FP lacked CD34 expression, whereas 42.5% of these cells had exited from G,/G,, resulting in a 10-fold increase in cell number. Approximately a 15-fold increase in cell number was observed in LTBMC receiving c-kit ligand and FP, with 45% of these cells entering into S and G2 + M phases of the cell cycle. This cellular expansion coupled with the fact that 20% of these cells expressed the original CD34+ phenotype indicated that in these cultures, a 2.9-fold increase in the number of CD34' cells was achieved.
We next attempted to investigate PHPC expansion by replating day 28 primary HPP-CFC cloned from R' cells in the presence of c-kit ligand and FP (Fig 3) . Based on the type of secondary colonies formed after replating, three groups of primary HPP-CFC colonies could be identified. The first group (10%) were unable to sustain the growth of any type of secondary colonies. The second group of colonies (47%) contained cells capable of giving rise to only secondary CFU-GM colonies. Individual primary HPP-CFC colonies of this type each contained between l and 25 CFU-GM. Primary HPP-CFC-derived colonies that made up the third group (43% of all colonies analyzed) contained cells that, in addition to being capable of giving rise to secondary CFU-GM colonies (14.2 f 4.9 [mean * SD]; range 6 to 26 CFU-GM/primary HPP-CFC), also formed secondary HPP-CFC-derived colonies. A range of one to six with an average of 3.5 secondary HPP-CFC were formed on the replating of such individual primary HPP-CFC.
Replating of primary HPP-CFC colonies.
DISCUSSION
Efforts to study the in vitro self-renewal capacity of human PHPC have been previously hampered by the lack of purified populations of PHPC and appropriate assay systems with which to assess PHPC behaviour. Although LTBMC have been successfully used to sustain human hematopoiesis in vitro, these culture systems have resulted in lineage-restricted expansion of committed progenitor ~e l l s . '~~'~~~~ The use of only partially purified BM cell fractions, inadequate cytokine, or growth factor supplementation and the inability to identify test parameters capable of assessing PHPC self-renewal may, in fact, be among the most important reasons for the failure to document in vitro expansion of primitive hematopoietic progenitor cells.
HPP-CFC25,29 are characterized by their resistance to 5-f l u o r o~r a c i l ,~~ their ability to form secondary multilineage colonies3* and, in the mouse system, by their similarity to marrow-repopulating cells.2',28,40 In fact, Bertoncello et aI4' originally found no evidence linking HPP-CFC with BMreconstituting potential only to report in subsequent studies that HPP-CFC are among the most primitive progenitor cells that can be detected in vitro42 and are related to stem cells with long-term BM-repopulating capacity, especially those isolated from BM fractions displaying dim R 123 staining. 33 These characteristics of HPP-CFC prompted McNiece et a128 to suggest that these colonies are an excellent model for the study of primitive hematopoietic stem cell behavior in vitro. In the present experiments, the behavior of HPP-CFC in a stromal cell-free LTBMC system was used to measure the generation and expansion of PHPC in vitro.
The R' fraction of CD34+ HLA-DR-CDl5-population of human BM cells was found to be selectively enriched for HPP-CFC and the LTBMC-IC. Such a separation of HPP-CFC based on R 123 fluorescence has been previously reported in the murine system33 and confirmed in humans by investigators at the Indiana University School of Medicine.I7 Although R++ cells contained assayable HPP-CFC, they did not contain LTBMC-IC, suggesting that HPP-CFC are closely related to LTBMC-IC but not necessarily identical. LTBMC initiated with R' human cells not only continued to produce HPP-CFC for a period of 4 weeks but were also capable of expanding by 5.5-fold the number of these primitive progenitor cells. Of interest is the fact that the production of HPP-CFC in LTBMC coincided with the continued presence of CD34' HLA-DR-cells in these cultures confirming earlier indications that PHPC are present among cells of this phe- notype.3,4.8,14.17.43 Th' is observation indicates that monitoring this cell phenotype during LTBMC may be an accurate and direct means of assessing PHPC self-renewal in vitro. In fact we have shown that reisolated CD34' HLA-DR-cells from 2-week-old primary LTBMC contain LTBMC-IC, which are capable of reinitiating secondary LTBMC with proliferating and progenitor cell production capabilities similar to those observed in primary LTBMC (data not shown).
A plausible explanation for the observed expansion of HPP-CFC in LTBMC is the ability of R+ cells to undergo selfrenewal, albeit to a limited degree. Recently, the observed expansion of murine HPP-CFC in delta assays in response to multiple cytokine stimulation was attributed to PHPC selfr e n e~a l .~' It is unlikely that the reported expansion of HPP-CFC in the present studies can be attributed to the recruitment of quiescent cells present in the original inoculum of PHPC because serial cloning of primary HPP-CFC colonies showed the presence of cells within these colonies capable of forming secondary HPP-CFC, an observation consistent with self-renewal. Furthermore, R+ cells underwent multilineage differentiation in vitro as shown by their ability to sustain, in addition to the production of HPP-CFC, the production of both CFU-GM and CFU-MK colonies for 8 weeks.
In this report the early developmental status of human HPP-CFC has been further supported by the ability of cells from these colonies to form, on replating, secondary hematopoietic colonies. The replating ability of murine HPP-CFC has been previously shown by McNiece et al.28.32 This group has shown that replated day 4 primary murine colonies, which would have otherwise developed into HPP-CFC, formed secondary colonies including secondary HPP-CFC. Several important methodologic differences exist between the present study and those of McNiece et al.2s332 In our studies fully developed day 28 HPP-CFC colonies possessed the ability to produce additional HPP-CFC. In addition, replated HPP-CFC in the studies of McNiece et a132 failed to form secondary HPP-CFC under the original culture conditions utilized for the primary plating (HPP-CFC 1 v HPP-CFC 2). By contrast, day 28 primary HPP-CFC in the present studies formed secondary HPP-CFC colonies under the identical culture conditions used during the primary plating. Whether secondary HPP-CFC detected in our studies in the presence of multiple cytokines represent, as described by Bertoncello et a1: * more committed HPP-CFC, which can respond to only one or two cytokines (in contrast to more primitive HPP-CFC that respond to a three-cytokine combination only), cannot be ruled out. However, because the progenitors of secondary HPP-CFC were recovered after 28 days, these findings suggest that a subpopulation of cells within primary HPP-CFC resemble the original progenitor cell from which the primary colony was derived. Whether the HPP-CFC described here represent the human homologue of the murine HPP-CFC 126328. 44 or a more primitive class of HPP-CFC capable of self-renewal cannot be resolved by these studies. It is possible that the differences observed between our studies and those of McNiece et al could be because of our use of c-kit ligand, a cytokine previously shown to affect primitive hematopoietic progenitor cells d i r e~t l y .~,~~,~~ However, these studies do indicate that a hierarchy of HPP-CFC based on self-renewal and differentiation potential exists.
This report also provides insight into the effects of cytokines on in vitro PHPC generation and expansion. The maintenance of the cells expressing the original phenotype used to initiate LTBMC was best achieved with c-kit ligand. On the other hand, FP with its IL-3 and GM-CSF moieties, both of which stimulate proliferation and differentiation:6 failed to sustain the continued presence of CD34-expressing cells. IL-3 has been previously shown to induce cell cycle progression and the expression of HLA-DR by CD34' HLA-DR-cells, two characteristics associated with differentiation of PHPC. 38 These studies suggest that the in vitro expansion of PHPC is dependent on a delicate balance between cytokines capable of inducing cellular expansion and others responsible for the maintenance of cells expressing CD34'. From this report it is apparent that in vitro PHPC expansion and possibly selfrenewal does occur and that it is in part a cytokine-dependent event. The further use of highly purified populations of PHPC and appropriate cytokine combinations will likely facilitate further assessment of this process. Such efforts will provide new insights into the biology of PHPC and might result in optimization of the PHPC content of BM grafts used for clinical marrow transplantation.
